15:20 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; leukemia Cell culture and mouse studies suggest promoting phagocytosis mediated by CALR-asialoglycan binding could help treat colorectal cancer and leukemia. In two human colorectal cancer and two human leukemia cell lines co-cultured...
21:32 , Sep 19, 2018 |  BC Innovations  |  Translation in Brief

To eat and not to eat

A Nature Communications paper published last month by Forty Seven Inc. (NASDAQ:FTSV) co-founder Irving Weissman and colleagues at Stanford University highlights a new strategy for boosting “eat me” signals on cancer cells that could complement...
15:48 , May 24, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles that target tumors and promote tumor cell phagocytosis could be used to treat cancer. The nanoparticles consisted of carboxylated polystyrene with two components conjugated to their surfaces: mAbs targeting tumor antigens, and calreticulin...
22:30 , Dec 7, 2016 |  BC Week In Review  |  Company News

Qiagen sales and marketing update

Qiagen launched its ipsogen CALR RGQ PCR Kit in Europe to aid in diagnosis of myeloproliferative neoplasms. The real-time PCR assay detects Type I and I calreticulin (CALR) mutations and mutations in the CALR exon...
23:51 , Nov 21, 2016 |  BioCentury  |  Product Development

AML Takes ASH

An analysis of the nearly 5,000 abstracts to be presented at the American Society of Hematology meeting shows research on acute myelogenous leukemia will dominate. BioCentury analyzed more than 2,200 abstracts concerning clinical research, including studies...
07:00 , Aug 25, 2016 |  BC Innovations  |  Targets & Mechanisms

Forty Seven and counting

With companies lining up to block CD47 for cancer, the cell surface protein is emerging as one of the top new targets in oncology. But the list of suitors could be about to get a...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Tumor-homing peptides CGKRK and RGF for targeting therapies to the placenta

Drug delivery TECHNOLOGY: Peptides Tumor-homing peptides could be used to target therapies to the placenta. In pregnant mice, the peptides CGKRK and RGF, which bind tumor antigens calreticulin (CALR) and integrin α5 (CD49e), respectively, accumulated primarily in...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Qiagen, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences deal

CeMM granted Qiagen an exclusive, worldwide license to the calreticulin (CALR) biomarker. Qiagen plans to use the biomarker to develop a CALR diagnostic to aid in prognostic profiling and disease management of myeloproliferative neoplasms....
07:00 , Apr 14, 2014 |  BC Week In Review  |  Company News

Cancer Genetics sales and marketing update

Cancer Genetics launched its CALR mutation analysis test to help diagnose patients with essential thrombocythemia and primary myelofibrosis. The company offers the PCR-based test, which detects mutations in the calreticulin (CALR) gene from...